In this phase 2 study that enrolled 99 patients with advanced urothelial carcinoma carrying FGFR3 or FGFR2/3 genomic alterations, an RR of 40%, with 3% of patients obtaining a CR, was observed. The gene discussed is FGFR3; the disease is urothelial carcinoma.